Effect of Partially Hydrolyzed, Whey-based Infant Formulas on Growth and Tolerability in Healthy Term Infants

NCT ID: NCT05868408

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

234 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-17

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the effect of partially hydrolyzed, whey-based infant formulas on growth and gastrointestinal tolerance in healthy term infants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infant Nutritional Physiological Phenomena Infant Formula Infant Health Infant Development Growth and Development

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double-blind, randomized, controlled, multi-arm trial
Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control formula

CTRL, an infant formula with minimum protein content of 1.8g intact protein/100kcal

Group Type ACTIVE_COMPARATOR

Control Formula

Intervention Type OTHER

Infant formula made with intact protein - minimum 1.8g protein/100kcal

Experimental formula 1

EXPL1, an infant formula with minimum protein content of 1.9g hydrolyzed protein/100kcal

Group Type EXPERIMENTAL

Experimental Formula 1

Intervention Type OTHER

Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal

Experimental formula 2

EXPL2, an infant formula identical to EXPL1 but manufactured using a different partially hydrolyzed milk protein base

Group Type EXPERIMENTAL

Experimental Formula 2

Intervention Type OTHER

Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control Formula

Infant formula made with intact protein - minimum 1.8g protein/100kcal

Intervention Type OTHER

Experimental Formula 1

Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal

Intervention Type OTHER

Experimental Formula 2

Infant formula made with hydrolyzed protein - minimum 1.9g protein/100kcal

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent has been obtained from at least one parent (or other legally acceptable representative \[LAR\]), if applicable)
2. Infant gestational age ≥37 completed weeks
3. Infant birth weight of ≥2.5 kg and ≤4.5 kg
4. Singleton birth
5. Infant postnatal age ≤28 days (date of birth = day 0)
6. Mother has previously decided to fully formula-feed, and infant is no longer breastfeeding or receiving breast milk
7. Infant's parent(s)/LAR is of legal age of majority, must understand the informed consent form and other relevant study documents, and is willing and able to fulfill the requirements of the study protocol

Exclusion Criteria

1. Chronic infectious, metabolic, genetic illness or other disease, including any condition that impacts feeding or growth
2. Major congenital or chromosomal abnormality known to affect growth (e.g., congenital heart disease, cystic fibrosis)
3. Maternal medical conditions known to affect infant growth (e.g., untreated preeclampsia or gestational diabetes)
4. Infants with special dietary needs other than standard infant formula
5. Infants with known (or symptoms suggestive of) cow's milk protein intolerance/allergy, or lactose intolerance or severe food allergies that impact diet
6. Child has other medical or psychiatric condition that, in the judgement of the investigator, would make the child inappropriate for entry into the study
7. Currently participating or having participated in another interventional clinical trial prior to enrollment
Minimum Eligible Age

0 Days

Maximum Eligible Age

28 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Société des Produits Nestlé (SPN)

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Guard Hospital

Jeddah, , Saudi Arabia

Site Status RECRUITING

King Faisal Specialist Hospital and Research Center

Riyadh, , Saudi Arabia

Site Status COMPLETED

National Guard Hospital

Riyadh, , Saudi Arabia

Site Status ACTIVE_NOT_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Saudi Arabia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Anthony de Cozar

Role: CONTACT

Phone: +41 21 785 8573

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mohammed Al-Hindi

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21.10.INF

Identifier Type: -

Identifier Source: org_study_id